866-997-4948(US-Canada Toll Free)

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2015

Published By :

Global Markets Direct

Published Date : Dec 2015

Category :

Cancer

No. of Pages : 1022 Pages

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2015

Summary

Global Markets Directs, Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2015, provides an overview of the Kidney Cancer (Renal Cell Cancer)s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Kidney Cancer (Renal Cell Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Cancer (Renal Cell Cancer) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Kidney Cancer (Renal Cell Cancer) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Kidney Cancer (Renal Cell Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Kidney Cancer (Renal Cell Cancer) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Kidney Cancer (Renal Cell Cancer)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 9
Kidney Cancer (Renal Cell Cancer) Overview 10
Therapeutics Development 11
Kidney Cancer (Renal Cell Cancer) - Therapeutics under Development by Companies 13
Kidney Cancer (Renal Cell Cancer) - Therapeutics under Investigation by Universities/Institutes 25
Kidney Cancer (Renal Cell Cancer) - Pipeline Products Glance 26
Kidney Cancer (Renal Cell Cancer) - Products under Development by Companies 30
Kidney Cancer (Renal Cell Cancer) - Products under Investigation by Universities/Institutes 46
Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development 47
Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment 180
Drug Profiles 211
Kidney Cancer (Renal Cell Cancer) - Recent Pipeline Updates 662
Kidney Cancer (Renal Cell Cancer) - Dormant Projects 965
Kidney Cancer (Renal Cell Cancer) - Dormant Projects 965
Kidney Cancer (Renal Cell Cancer) - Discontinued Products 984
Kidney Cancer (Renal Cell Cancer) - Product Development Milestones 988
Appendix 997

List of Tables
Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H2 2015 35
Number of Products under Development for Kidney Cancer (Renal Cell Cancer) - Comparative Analysis, H2 2015 36
Number of Products under Development by Companies, H2 2015 38
Number of Products under Development by Companies, H2 2015 (Contd..1) 39
Number of Products under Development by Companies, H2 2015 (Contd..2) 40
Number of Products under Development by Companies, H2 2015 (Contd..3) 41
Number of Products under Development by Companies, H2 2015 (Contd..4) 42
Number of Products under Development by Companies, H2 2015 (Contd..5) 43
Number of Products under Development by Companies, H2 2015 (Contd..6) 44
Number of Products under Development by Companies, H2 2015 (Contd..7) 45
Number of Products under Development by Companies, H2 2015 (Contd..8) 46
Number of Products under Development by Companies, H2 2015 (Contd..9) 47
Number of Products under Development by Companies, H2 2015 (Contd..10) 48
Number of Products under Investigation by Universities/Institutes, H2 2015 49
Comparative Analysis by Late Stage Development, H2 2015 50
Comparative Analysis by Clinical Stage Development, H2 2015 51
Comparative Analysis by Early Stage Development, H2 2015 52
Comparative Analysis by Unknown Stage Development, H2 2015 53
Products under Development by Companies, H2 2015 54
Products under Development by Companies, H2 2015 (Contd..1) 55
Products under Development by Companies, H2 2015 (Contd..2) 56
Products under Development by Companies, H2 2015 (Contd..3) 57
Products under Development by Companies, H2 2015 (Contd..4) 58
Products under Development by Companies, H2 2015 (Contd..5) 59
Products under Development by Companies, H2 2015 (Contd..6) 60
Products under Development by Companies, H2 2015 (Contd..7) 61
Products under Development by Companies, H2 2015 (Contd..8) 62
Products under Development by Companies, H2 2015 (Contd..9) 63
Products under Development by Companies, H2 2015 (Contd..10) 64
Products under Development by Companies, H2 2015 (Contd..11) 65
Products under Development by Companies, H2 2015 (Contd..12) 66
Products under Development by Companies, H2 2015 (Contd..13) 67
Products under Development by Companies, H2 2015 (Contd..14) 68
Products under Development by Companies, H2 2015 (Contd..15) 69
Products under Investigation by Universities/Institutes, H2 2015 70
Kidney Cancer (Renal Cell Cancer) - Pipeline by 4SC AG, H2 2015 71
Kidney Cancer (Renal Cell Cancer) - Pipeline by AbbVie Inc., H2 2015 72
Kidney Cancer (Renal Cell Cancer) - Pipeline by Acceleron Pharma, Inc., H2 2015 73
Kidney Cancer (Renal Cell Cancer) - Pipeline by Advanced Cancer Therapeutics, H2 2015 74
Kidney Cancer (Renal Cell Cancer) - Pipeline by Advaxis, Inc., H2 2015 75
Kidney Cancer (Renal Cell Cancer) - Pipeline by Advenchen Laboratories, LLC, H2 2015 76
Kidney Cancer (Renal Cell Cancer) - Pipeline by Alethia Biotherapeutics Inc., H2 2015 77
Kidney Cancer (Renal Cell Cancer) - Pipeline by Altor BioScience Corporation, H2 2015 78
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ambrx, Inc., H2 2015 79
Kidney Cancer (Renal Cell Cancer) - Pipeline by Amgen Inc., H2 2015 80
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015 81
Kidney Cancer (Renal Cell Cancer) - Pipeline by APEIRON Biologics AG, H2 2015 82
Kidney Cancer (Renal Cell Cancer) - Pipeline by arGEN-X BV, H2 2015 83
Kidney Cancer (Renal Cell Cancer) - Pipeline by Argos Therapeutics, Inc., H2 2015 84
Kidney Cancer (Renal Cell Cancer) - Pipeline by ArQule, Inc., H2 2015 85
Kidney Cancer (Renal Cell Cancer) - Pipeline by Arrowhead Research Corporation, H2 2015 86
Kidney Cancer (Renal Cell Cancer) - Pipeline by Astellas Pharma Inc., H2 2015 87
Kidney Cancer (Renal Cell Cancer) - Pipeline by AstraZeneca Plc, H2 2015 88
Kidney Cancer (Renal Cell Cancer) - Pipeline by ATLAB Pharma SAS, H2 2015 89
Kidney Cancer (Renal Cell Cancer) - Pipeline by Aurigene Discovery Technologies Limited, H2 2015 90
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bayer AG, H2 2015 91
Kidney Cancer (Renal Cell Cancer) - Pipeline by Beta Pharma, Inc., H2 2015 92
Kidney Cancer (Renal Cell Cancer) - Pipeline by Beth Israel Deaconess Medical Center, Inc., H2 2015 93
Kidney Cancer (Renal Cell Cancer) - Pipeline by BIND Therapeutics, Inc., H2 2015 94
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bio-Cancer Treatment International Limited, H2 2015 95
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionomics Limited, H2 2015 96
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionovis SA, H2 2015 97
Kidney Cancer (Renal Cell Cancer) - Pipeline by Boehringer Ingelheim GmbH, H2 2015 98
Kidney Cancer (Renal Cell Cancer) - Pipeline by Boston Biomedical, Inc., H2 2015 99
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bristol-Myers Squibb Company, H2 2015 100
Kidney Cancer (Renal Cell Cancer) - Pipeline by Caladrius Biosciences, Inc. , H2 2015 101
Kidney Cancer (Renal Cell Cancer) - Pipeline by Calithera Biosciences, Inc., H2 2015 102
Kidney Cancer (Renal Cell Cancer) - Pipeline by CASI Pharmaceuticals Inc., H2 2015 103
Kidney Cancer (Renal Cell Cancer) - Pipeline by Celgene Corporation, H2 2015 104
Kidney Cancer (Renal Cell Cancer) - Pipeline by Cellceutix Corporation, H2 2015 105
Kidney Cancer (Renal Cell Cancer) - Pipeline by Celldex Therapeutics, Inc., H2 2015 106
Kidney Cancer (Renal Cell Cancer) - Pipeline by Celltrion, Inc., H2 2015 107
Kidney Cancer (Renal Cell Cancer) - Pipeline by Cerulean Pharma, Inc., H2 2015 108
Kidney Cancer (Renal Cell Cancer) - Pipeline by Chipscreen Biosciences Ltd, H2 2015 109
Kidney Cancer (Renal Cell Cancer) - Pipeline by Corcept Therapeutics Incorporated, H2 2015 110
Kidney Cancer (Renal Cell Cancer) - Pipeline by Cytune Pharma SAS, H2 2015 111
Kidney Cancer (Renal Cell Cancer) - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015 112
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ecrins Therapeutics SAS, H2 2015 113
Kidney Cancer (Renal Cell Cancer) - Pipeline by EirGenix Inc., H2 2015 114
Kidney Cancer (Renal Cell Cancer) - Pipeline by Eisai Co., Ltd., H2 2015 115
Kidney Cancer (Renal Cell Cancer) - Pipeline by Eli Lilly and Company, H2 2015 116
Kidney Cancer (Renal Cell Cancer) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 117
Kidney Cancer (Renal Cell Cancer) - Pipeline by Erytech Pharma SA, H2 2015 118
Kidney Cancer (Renal Cell Cancer) - Pipeline by Esperance Pharmaceuticals, Inc., H2 2015 119
Kidney Cancer (Renal Cell Cancer) - Pipeline by Exelixis, Inc., H2 2015 120
Kidney Cancer (Renal Cell Cancer) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 121
Kidney Cancer (Renal Cell Cancer) - Pipeline by Genor BioPharma Co., Ltd., H2 2015 122
Kidney Cancer (Renal Cell Cancer) - Pipeline by GenSpera, Inc., H2 2015 123
Kidney Cancer (Renal Cell Cancer) - Pipeline by Genzyme Corporation, H2 2015 124
Kidney Cancer (Renal Cell Cancer) - Pipeline by GlaxoSmithKline Plc, H2 2015 125
Kidney Cancer (Renal Cell Cancer) - Pipeline by Glycotope GmbH, H2 2015 126
Kidney Cancer (Renal Cell Cancer) - Pipeline by HEC Pharm Co., Ltd., H2 2015 127
Kidney Cancer (Renal Cell Cancer) - Pipeline by Horizon Pharma Plc, H2 2015 128
Kidney Cancer (Renal Cell Cancer) - Pipeline by Hospira, Inc., H2 2015 129
Kidney Cancer (Renal Cell Cancer) - Pipeline by Hutchison MediPharma Limited, H2 2015 130
Kidney Cancer (Renal Cell Cancer) - Pipeline by immatics biotechnologies GmbH, H2 2015 131
Kidney Cancer (Renal Cell Cancer) - Pipeline by Immune Design Corp., H2 2015 132
Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunicum AB, H2 2015 133
Kidney Cancer (Renal Cell Cancer) - Pipeline by ImmunoFrontier, Inc., H2 2015 134
Kidney Cancer (Renal Cell Cancer) - Pipeline by ImmunoGen, Inc., H2 2015 135
Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunomedics, Inc., H2 2015 136
Kidney Cancer (Renal Cell Cancer) - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015 137
Kidney Cancer (Renal Cell Cancer) - Pipeline by Incyte Corporation, H2 2015 138
Kidney Cancer (Renal Cell Cancer) - Pipeline by Innate Immunotherapeutics Ltd, H2 2015 139
Kidney Cancer (Renal Cell Cancer) - Pipeline by InteRNA Technologies B.V., H2 2015 140
Kidney Cancer (Renal Cell Cancer) - Pipeline by Johnson & Johnson, H2 2015 141
Kidney Cancer (Renal Cell Cancer) - Pipeline by KAHR medical Ltd., H2 2015 142
Kidney Cancer (Renal Cell Cancer) - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 143
Kidney Cancer (Renal Cell Cancer) - Pipeline by KineMed, Inc., H2 2015 144
Kidney Cancer (Renal Cell Cancer) - Pipeline by Komipharm International Co., Ltd., H2 2015 145
Kidney Cancer (Renal Cell Cancer) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015 146
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mabion SA, H2 2015 147
Kidney Cancer (Renal Cell Cancer) - Pipeline by MacroGenics, Inc., H2 2015 148
Kidney Cancer (Renal Cell Cancer) - Pipeline by MediaPharma s.r.l., H2 2015 149
Kidney Cancer (Renal Cell Cancer) - Pipeline by MediGene AG, H2 2015 150
Kidney Cancer (Renal Cell Cancer) - Pipeline by MedImmune, LLC, H2 2015 151
Kidney Cancer (Renal Cell Cancer) - Pipeline by Medivation, Inc., H2 2015 152
Kidney Cancer (Renal Cell Cancer) - Pipeline by Merck & Co., Inc., H2 2015 153
Kidney Cancer (Renal Cell Cancer) - Pipeline by Merck KGaA, H2 2015 154
Kidney Cancer (Renal Cell Cancer) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 155
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mirati Therapeutics Inc., H2 2015 156
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mologen AG, H2 2015 157
Kidney Cancer (Renal Cell Cancer) - Pipeline by Monopar Therapeutics LLC, H2 2015 158
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mycenax Biotech Inc., H2 2015 159
Kidney Cancer (Renal Cell Cancer) - Pipeline by NanoSmart Pharmaceuticals, Inc., H2 2015 160
Kidney Cancer (Renal Cell Cancer) - Pipeline by Nektar Therapeutics, H2 2015 161
Kidney Cancer (Renal Cell Cancer) - Pipeline by NewLink Genetics Corporation, H2 2015 162
Kidney Cancer (Renal Cell Cancer) - Pipeline by Novartis AG, H2 2015 163
Kidney Cancer (Renal Cell Cancer) - Pipeline by Omeros Corporation, H2 2015 164
Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncobiologics, Inc., H2 2015 165
Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncolys BioPharma Inc., H2 2015 166
Kidney Cancer (Renal Cell Cancer) - Pipeline by OncoMax, H2 2015 167
Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncothyreon Inc., H2 2015 168
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 169
Kidney Cancer (Renal Cell Cancer) - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015 170
Kidney Cancer (Renal Cell Cancer) - Pipeline by Panacea Biotec Limited, H2 2015 171
Kidney Cancer (Renal Cell Cancer) - Pipeline by Panacela Labs, Inc., H2 2015 172
Kidney Cancer (Renal Cell Cancer) - Pipeline by Peloton Therapeutics, Inc., H2 2015 173
Kidney Cancer (Renal Cell Cancer) - Pipeline by Pfizer Inc., H2 2015 174
Kidney Cancer (Renal Cell Cancer) - Pipeline by PharmaEssentia Corporation, H2 2015 175
Kidney Cancer (Renal Cell Cancer) - Pipeline by Pharmicell Co., Ltd., H2 2015 176
Kidney Cancer (Renal Cell Cancer) - Pipeline by Pivotal BioSciences, Inc., H2 2015 177
Kidney Cancer (Renal Cell Cancer) - Pipeline by Plexxikon Inc., H2 2015 178
Kidney Cancer (Renal Cell Cancer) - Pipeline by Pono Pharma, H2 2015 179
Kidney Cancer (Renal Cell Cancer) - Pipeline by Prima BioMed Ltd., H2 2015 180
Kidney Cancer (Renal Cell Cancer) - Pipeline by PsiOxus Therapeutics Limited, H2 2015 181
Kidney Cancer (Renal Cell Cancer) - Pipeline by Qu Biologics Inc., H2 2015 182
Kidney Cancer (Renal Cell Cancer) - Pipeline by Recombio S.L, H2 2015 183
Kidney Cancer (Renal Cell Cancer) - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2015 184
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sanofi, H2 2015 185
Kidney Cancer (Renal Cell Cancer) - Pipeline by Seattle Genetics, Inc., H2 2015 186
Kidney Cancer (Renal Cell Cancer) - Pipeline by Selvita SA, H2 2015 187
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sevion Therapeutics, Inc., H2 2015 188
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sorrento Therapeutics, Inc., H2 2015 189
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 190
Kidney Cancer (Renal Cell Cancer) - Pipeline by Syndax Pharmaceuticals, Inc., H2 2015 191
Kidney Cancer (Renal Cell Cancer) - Pipeline by Taiwan Liposome Company, Ltd., H2 2015 192
Kidney Cancer (Renal Cell Cancer) - Pipeline by TC BioPharm Limited, H2 2015 193
Kidney Cancer (Renal Cell Cancer) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 194
Kidney Cancer (Renal Cell Cancer) - Pipeline by Theravectys SA, H2 2015 195
Kidney Cancer (Renal Cell Cancer) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 196
Kidney Cancer (Renal Cell Cancer) - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015 197
Kidney Cancer (Renal Cell Cancer) - Pipeline by TVAX Biomedical, Inc., H2 2015 198
Kidney Cancer (Renal Cell Cancer) - Pipeline by Tyrogenex, Inc., H2 2015 199
Kidney Cancer (Renal Cell Cancer) - Pipeline by Vascular Biogenics Ltd., H2 2015 200
Kidney Cancer (Renal Cell Cancer) - Pipeline by Vaxeal Holding SA, H2 2015 201
Kidney Cancer (Renal Cell Cancer) - Pipeline by Welichem Biotech Inc., H2 2015 202
Kidney Cancer (Renal Cell Cancer) - Pipeline by Zymeworks Inc., H2 2015 203
Assessment by Monotherapy Products, H2 2015 204
Assessment by Combination Products, H2 2015 205
Number of Products by Stage and Target, H2 2015 207
Number of Products by Stage and Mechanism of Action, H2 2015 223
Number of Products by Stage and Route of Administration, H2 2015 232
Number of Products by Stage and Molecule Type, H2 2015 234
Kidney Cancer (Renal Cell Cancer) Therapeutics - Recent Pipeline Updates, H2 2015 686
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H2 2015 989
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..1), H2 2015 990
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..2), H2 2015 991
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..3), H2 2015 992
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..4), H2 2015 993
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..5), H2 2015 994
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..6), H2 2015 995
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..7), H2 2015 996
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..8), H2 2015 997
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..9), H2 2015 998
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..10), H2 2015 999
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..11), H2 2015 1000
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..12), H2 2015 1001
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..13), H2 2015 1002
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..14), H2 2015 1003
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..15), H2 2015 1004
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..16), H2 2015 1005
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..17), H2 2015 1006
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..18), H2 2015 1007
Kidney Cancer (Renal Cell Cancer) - Discontinued Products, H2 2015 1008
Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..1), H2 2015 1009
Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..2), H2 2015 1010
Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..3), H2 2015 1011

List of Figures
Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H2 2015 35
Number of Products under Development for Kidney Cancer (Renal Cell Cancer) - Comparative Analysis, H2 2015 36
Number of Products under Development by Companies, H2 2015 37
Number of Products under Investigation by Universities/Institutes, H2 2015 49
Comparative Analysis by Late Stage Development, H2 2015 50
Comparative Analysis by Clinical Stage Development, H2 2015 51
Comparative Analysis by Early Stage Products, H2 2015 52
Assessment by Monotherapy Products, H2 2015 204
Assessment by Combination Products, H2 2015 205
Number of Products by Top 10 Targets, H2 2015 206
Number of Products by Stage and Top 10 Targets, H2 2015 206
Number of Products by Top 10 Mechanism of Actions, H2 2015 222
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 222
Number of Products by Top 10 Routes of Administration, H2 2015 231
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 231
Number of Products by Top 10 Molecule Types, H2 2015 233
Number of Products by Stage and Top 10 Molecule Types, H2 2015 233

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *